Additional Information Regarding the Acquisition of Trendlines' Portfolio Company ApiFix Ltd. by OrthoPediatrics Corp.

Estimated minimum total consideration of US$67 million before earnout
Trendlines' proportionate part of the minimum consideration estimated at US$13.2 million before earnout

Misgav, Israel – 3 April 2020 – Pursuant to the press release published on 2 April 2020, The Trendlines Group Ltd. ("Trendlines" or the "Company") is pleased to provide additional information relative to the 100% acquisition of portfolio company ApiFix Ltd. ("ApiFix"), a company focused on non-fusion treatment of progressive adolescent idiopathic scoliosis, by Nasdaq-traded OrthoPediatrics Corp, ("OrthoPediatrics"), a company focused exclusively on advancing the field of pediatric orthopedics (the "Acquisition"). The Acquisition was signed and closed on 1 April 2020 ("Closing Date"); Trendlines held 18.62% of ApiFix at closing.

The total value of the Acquisition, in the form of cash and common shares of OrthoPediatrics stock (NASDAQ: KIDS) including the Anniversary Payments, (as defined below), but not including the fourth year Earnout (as defined below), is approximately US$67 million.

At closing, ApiFix shareholders received an aggregate of 934,783 new common shares of OrthoPediatrics stock and US$0.8 million in cash, representing approximately US$38 million (based on the March 31, 2020 OrthoPediatrics closing share price of US$39.64 per share). Additionally, guaranteed milestone payments ("Anniversary Payments"), in the form of cash, or cash and OrthoPediatrics common shares, will be made as follows:

(i) US$13 million, of which at least 25% will be paid in cash, on the second anniversary of the Closing Date, provided that such payment will be paid earlier if 150 clinical procedures using the ApiFix System are completed in the United States before such anniversary date;
(ii) US$8 million, of which at least 25% will be paid in cash, on the third anniversary of the Closing Date; and
(iii) US$9 million, of which at least 25% will be paid in cash, on the fourth anniversary of the Closing Date.

In addition, to the extent that the product of OrthoPediatrics' revenues from the ApiFix System for the twelve months ended June 30, 2024 multiplied by 2.25 exceeds the US$17 million Anniversary Payments actually made for the third and fourth years, OrthoPediatrics will pay the ApiFix shareholders the amount of the excess ("Earnout").

The Company is entitled to its proportionate share of the consideration for the Acquisition based on its 18.62% interest in ApiFix at closing, or approximately US$13.2 million not including earnout proceeds. For Earnout illustration purposes only, it is noted that if the fourth year sales of the ApiFix System are US$20 million, the Earnout will be US$28 million and the Company's share of such Earnout will be an additional US$5.2 million, and; if the fourth year sales of the ApiFix System are US$40 million, then the Earnout will be US$73 million and the Company's share of such Earnout will be an additional US$13.6 million. The Company will provide further updates when it receives its proportionate share of the Anniversary Payments and/or Earnout payments.

The consideration was arrived at following arm's length negotiations between OrthoPediatrics and the ApiFix shareholders.

Trendlines' last valuation of ApiFix prior to the Acquisition negotiations, as represented in the Company's unaudited financial statements as at 30 September 2019 (being Trendlines' last valuation of ApiFix prior to the Acquisition negotiations) was US$3.5 million. The minimum guaranteed consideration due to Trendlines from the Acquisition is US$13.2 million.

The Company estimates that, excluding any proceeds from the Earnout, its multiple on the ApiFix investment is 15x and its Internal Rate of Return (IRR) is 37%.

The exit by Trendlines from its direct shareholdings of ApiFix pursuant to the Acquisition had contributed positively to the consolidated earnings per share and net assets per share of the Group for the financial year ended 31 December 2019[1] ("FY2019"). In the financial year ending 31 December 2020 ("FY2020"), Trendlines' shareholdings in ApiFix will be converted into cash, short- and long-term receivables, and short- and long-term investments. As such, the Acquisition will not have a material effect on the consolidated net assets per share of the Group for FY2020. However, the Acquisition is expected to contribute positively to the consolidated earnings per share of the Group for FY2020.

Conference Call and Webcast Information

The Company will be holding an investor conference call on Tuesday 7 April 2020 at 13:00 (Singapore time) to discuss the Acquisition, followed by a question and answer session. To listen to the live conference call, please dial:

+65 3157 2876 for Singapore
+972 3-376-5236 for Israel, Tel Aviv (Toll)
+1 872-233-8019 for US or
Join at this link: **Join conference call**
The conference ID number is: 562 236 865#

[1] *Please refer to the "Financial Highlights and Review" section of the Company's Annual Report for FY2019 and Note 9(B)(2) to the financial statements for FY2019 for further information.*

About The Trendlines Group

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Associate Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).

Investor Contact Information
Israel:
Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore and China:
Reyna MEI, Financial PR
reyna@financialpr.com.sg
Tel: +65.6438.2990